HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing disruptive medical technologies to his new role, where he will be essential in the company’s strategic direction, commercialization efforts, and day-to-day operations. Eno noted that he believes HeartBeam’s technology will be able to make a major impact on the lives of the millions of people who suffer from cardiac-related issues. In previous positions, which included CEO of Preview Medical Inc. and senior VP for Heartflow Inc., Eno has created go-to-market strategies for an array of breakthrough products including noninvasive FFR CT (“FFR CT”) diagnostic for coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation and intravascular brachytherapy. He has led all aspects of marketing and product functions for a new category of personalized, noninvasive testing for heart disease and has held senior marketing and sales leadership roles at OptiMedica, NeoGuide Systems and Avantec Vascular. “We have a tremendous opportunity to accelerate our company growth as we move forward on our commercialization path, and we’re excited to have Rob join our leadership team,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “Rob has extensive experience bringing innovative medical technology products to market, which will be invaluable as we move forward with plans to broaden our product portfolio pipeline.”
To view the full press release, visit https://ibn.fm/7B47W
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.